Search details
1.
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Haematologica
; 106(1): 56-63, 2021 01 01.
Article
in English
| MEDLINE | ID: mdl-31896684
2.
The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades.
J Exp Med
; 200(6): 737-47, 2004 Sep 20.
Article
in English
| MEDLINE | ID: mdl-15381729
3.
Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents.
Rheumatology (Oxford)
; 49(11): 2172-80, 2010 Nov.
Article
in English
| MEDLINE | ID: mdl-20675707
4.
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
Blood Adv
; 2(20): 2658-2671, 2018 10 23.
Article
in English
| MEDLINE | ID: mdl-30327374
5.
Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.
Leukemia
; 36(6): 1689-1692, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35347238
6.
Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.
Cancer Res
; 64(9): 3271-5, 2004 May 01.
Article
in English
| MEDLINE | ID: mdl-15126369
7.
Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.
Am J Pharmacogenomics
; 5(1): 35-43, 2005.
Article
in English
| MEDLINE | ID: mdl-15727487
8.
Cancer patient perceptions on the ethical and legal issues related to biobanking.
BMC Med Genomics
; 6: 8, 2013 Mar 08.
Article
in English
| MEDLINE | ID: mdl-23497701
9.
The prevalence and accuracy of self-reported history of 11 autoimmune diseases.
J Rheumatol
; 35(10): 2001-4, 2008 Oct.
Article
in English
| MEDLINE | ID: mdl-18785310
10.
Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity.
Arthritis Res Ther
; 10(5): R108, 2008.
Article
in English
| MEDLINE | ID: mdl-18783591
11.
MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.
Blood
; 108(10): 3465-71, 2006 Nov 15.
Article
in English
| MEDLINE | ID: mdl-16849642
12.
Insights from the gene expression profiling of multiple myeloma.
Curr Hematol Rep
; 3(1): 67-73, 2004 Jan.
Article
in English
| MEDLINE | ID: mdl-14695854
13.
A molecular compendium of genes expressed in multiple myeloma.
Blood
; 100(6): 2175-86, 2002 Sep 15.
Article
in English
| MEDLINE | ID: mdl-12200383
Results
1 -
13
de 13
1
Next >
>>